Clinical Trials · NCT04515576
A Study of LY3493269 in Participants With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 56
- Start date
- Aug 2020
- Locations
- 3 sites, United States
- Primary endpoint
- Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration